 |
SKDK and ICR handle Intra-Cellular Therapies as it is getting acquired by Johnson & Johnson for $14.6B.
J&J is offering $132 for each of the Intra-Cellular shares that trade on the NASDAQ.
The Financial Times reports the transaction is the biggest biotech deal since Pfizer acquired Seagen in 2023 for $46B.
Intra-Cellular works on treatments for central nervous system disorders—including major depressive disorder, generalized anxiety disorder and Parkinson’s disease.
Its Caplyta, a once-daily pill, is the only treatment that the Food & Drug Administration has approved to treat adults with schizophrenia and episodes associated with bipolar disorder depression.
About 2.4M adults live with schizophrenia, while 6.1M suffer from bipolar disorder.
Intra-Cellular CEO Sharon Mates said J&J ownership will enable her Bedminster, NJ-based company to reach even more patients around the world.
SKDK’s Erin Weinstein handles media for Intra-Cellular, while Juan Sanchez works Wall Street.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
